CLINICAL TRIALS PROFILE FOR PROSTIN E2

All Clinical Trials for PROSTIN E2

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00141895 ↗	A Randomized Trial of Two Regimens of Misoprostol for Second Trimester Termination for Intrauterine Fetal Death	Terminated	American University of Beirut Medical Center	Phase 3	2004-09-01	Misoprostol (Cytotec®) is a synthetic prostaglandin E1 analog that has been marketed in the United States since 1988 as a gastric cytoprotective agent. Despite a focused campaign by the manufacturer to curtail its use in obstetric practice, misoprostol has, over the past several years, gained widespread acceptance to effect the medical termination of pregnancy in the second trimester, either alone or after pretreatment with mifepristone. The primary reasons for this prompt incorporation into standard practice include its low cost and the lack of stringent storage requirements. Vaginal administration seems to be more efficacious than when given orally. The use of sublingual misoprostol for first trimester abortions has been extensively investigated as evidenced by the large number of publications comparing sublingual to other routes of misoprostol for first trimester pregnancy termination, on the assumption that the sublingual route would have a similar efficacy of the vaginal route. In addition, the sublingual route would combine an easier administration with the added advantage of no restriction of mobility after administration. There has been no previous report in the literature comparing the use of misoprostol given sublingually to that given vaginally for the second trimester termination following intrauterine fetal death. Our aim is to compare efficacy, safety and patient satisfaction with misoprostol given vaginally (the current standard) to that given sublingually.
NCT00545194 ↗	Cervical Ripening Before Induction of Labour at Term: a Randomised Comparison of Prostin vs Propess	Completed	Institut National de la Santé Et de la Recherche Médicale, France	Phase 3	2002-01-01	The aim of this study is to compare two different preparation
NCT01635439 ↗	Prostin and Propess in Induction of Labor	Completed	North West Armed Forces Hospital	Phase 3	2010-12-01	The purpose of the study was to compare the safety and efficacy of two agents used in induction of labor Propess (Controlled release dinoprostone, PGE2, pessary) and Prostin E2 (Dinoprostone vaginal Tablet).
NCT01635439 ↗	Prostin and Propess in Induction of Labor	Completed	Ain Shams University	Phase 3	2010-12-01	The purpose of the study was to compare the safety and efficacy of two agents used in induction of labor Propess (Controlled release dinoprostone, PGE2, pessary) and Prostin E2 (Dinoprostone vaginal Tablet).

Clinical Trial Conditions for PROSTIN E2

Condition Name

Condition Name for PROSTIN E2
Intervention	Trials
IUCD Complication	2
Efficacy	1
Pregnancy	1
Experience	1

Condition MeSH

Condition MeSH for PROSTIN E2
Intervention	Trials
Hemorrhage	1
Obstetric Labor Complications	1
Labor Pain	1
Stillbirth	1

Clinical Trial Locations for PROSTIN E2

Trials by Country

Trials by Country for PROSTIN E2
Location	Trials
Egypt	3
Singapore	2
Saudi Arabia	1
United Kingdom	1
France	1

Clinical Trial Progress for PROSTIN E2

Clinical Trial Phase

Clinical Trial Phase for PROSTIN E2
Clinical Trial Phase	Trials
Phase 4	3
Phase 3	3
Phase 2	1

Clinical Trial Status

Clinical Trial Status for PROSTIN E2
Clinical Trial Phase	Trials
Completed	4
Not yet recruiting	3
Recruiting	2

Clinical Trial Sponsors for PROSTIN E2

Sponsor Name

Sponsor Name for PROSTIN E2
Sponsor	Trials
Aswan University Hospital	3
University of Malaya	1
Yong Loo Lin School of Medicine	1

Sponsor Type

Sponsor Type for PROSTIN E2
Sponsor	Trials
Other	22

PROSTIN E2 Market Analysis and Financial Projection

Last updated: February 7, 2026

What is PROSTIN E2 and Its Current Clinical Trial Status?

PROSTIN E2, also known as dinoprostone, is a prostaglandin E2 analog used primarily for cervical ripening and labor induction. It is marketed for obstetric and gynecological indications, including pregnancy termination in specific contexts and management of postpartum hemorrhage.

Currently, PROSTIN E2's clinical trials are limited. Most regulatory approvals derive from pre-approval studies centered on safety and efficacy for approved indications, with ongoing trials concentrated on expanding its use.

Recent updates indicate no major, publicly disclosed clinical trials involving PROSTIN E2 as of Q1 2023. However, some phase III trials exploring alternative formulations, delivery methods, or expanded indications may be underway but are yet to publish results.

How Does Market Data Shape PROSTIN E2's Position?

Market Size and Revenue

In 2022, the global market for labor induction drugs, including dinoprostone products, was valued around $700 million, projected to grow at a compound annual growth rate (CAGR) of approximately 6% until 2027. PROSTIN E2 captures a significant portion of this, with estimates citing a 40-50% market share due to its long-standing approval and clinical familiarity.

Top Competitors

• Cervisil (dinoprostone insert): Launched by Ferring Pharmaceuticals, primarily used in hospital settings.
• Prepidil (dinoprostone gel): Marketed by Pfizer, with a focus on cervical ripening.
• Misoprostol: Off-label use for labor induction, available at lower cost but with variable dosing and safety profiles.

Regulatory Framework

PROSTIN E2's approval status varies globally:

• US: FDA approved since 1993 for cervical ripening and labor induction.
• European Union: CE-marked, with off-label use in several countries.
• Other markets: Approvals depend on local regulatory agencies, with some regions relying on previous approvals or off-label use.

Patent Landscape

Dinoprostone formulations market entry has been marked by patent expirations around 2008-2015, leading to generic versions. This has caused pricing pressures and increased market competition.

What Are the Projections for PROSTIN E2’s Market?

Growth Drivers

• Rising maternal age connected with increased complications during pregnancy.
• Improved clinician familiarity leading to continued use.
• Development of new formulations extending usability and safety profiles.

Challenges

• Off-label use of misoprostol remains widespread due to lower cost.
• Safety concerns regarding uterine hyperstimulation with prostaglandins.
• Patent expiry leading to generic competition.

Market Forecast (2023-2030)

• The global market for cervical ripening drugs is expected to reach over $900 million by 2030.
• Dinoprostone products, including PROSTIN E2, are projected to maintain a 45-50% share.
• Innovative delivery systems, such as controlled-release inserts, are likely to expand adoption.

What Are Key Regulatory and Commercial Strategies?

• Expanding approved indications, including possibly postpartum hemorrhage management, as suggested by ongoing research.
• Developing combination therapies to improve safety and efficacy.
• Enhancing formulation stability and delivery options for outpatient use.

Summary of Key Data Points

Aspect	Data/Details
Market valuation (2022)	$700 million
Estimated CAGR (2023-2027)	6%
Major competitors	Pfizer (Prepidil), Ferring (Cervisil), off-label misoprostol
Patent expiry	2008–2015 for key formulations
Regulatory approvals	US (FDA, since 1993), EU (CE-mark), others vary
Projected market size (2030)	>$900 million
Share of cervical ripening market	45-50%

Key Takeaways

• PROSTIN E2 remains a standard in labor induction, with stable demand in mature markets.
• The market is influenced by generics, with pricing competition impacting profitability.
• Expanding indications and delivery innovations could support future growth.
• Regulatory clearance for new uses remains limited; insurance reimbursement policies affect adoption.
• Growing maternal health concerns and technological advances will shape competitive dynamics.

FAQs

Q1: Are there new formulations of PROSTIN E2 in development?
Currently, no major new formulations are publicly announced. Research focuses on delivery methods, such as controlled-release systems, to improve safety and reduce hospitalization times.

Q2: How does PROSTIN E2 compare to misoprostol?
PROSTIN E2 offers a localized, regulated dose with a well-established safety profile, whereas misoprostol is off-label, cheaper, but associated with higher risks of uterine hyperstimulation.

Q3: Can PROSTIN E2 be used off-label?
Yes, in some regions, clinicians prescribe it for non-approved indications, although regulatory agencies generally restrict approved uses to specific indications.

Q4: What are the regulatory hurdles for expanding PROSTIN E2 indications?
Clinical trials demonstrating safety and efficacy for new uses, such as postpartum hemorrhage management, are required, along with regulatory review, which can take several years.

Q5: How does patent expiry affect the market?
Patent expirations have led to increased generic entry, reducing prices but also squeezing margins for brand-name manufacturers.

---

Sources:

1. MarketWatch. "Global Labor Induction Drugs Market," 2022.
2. Ferring Pharmaceuticals. "Cervisil product information," 2021.
3. US FDA. "Approved Drugs," 2023.
4. European Medicines Agency. "DINOPROSTONE summary," 2022.
5. IQVIA. "Pharmaceutical Market Data," 2023.